The goal of this study is to determine what effect Cetaphil® Restoraderm® system has on babies' skin versus Johnson \& Johnson baby lotion and skin cleanser.
Subjects will randomly be divided into a group using Cetaphil® Restoraderm® system or a group using Johnson \& Johnson baby lotion and skin cleanser . At 3, 6, and 12 months non-invasive measurements of barrier function will be used to test the babies' skin. The procedures are as follows: * Transepidermal loss (TEWL - measures the water loss from the skin) * Skin electrical capacitance (measures how much water stays in the top layer of skin) * Skin pH (measures level of pH) * Skin microbiome analysis (skin swabs to check genetic code of skin bacteria) * Lipidomic and natural moisturizing factor analysis (measures lipids (oils) in the top layer of skin) Both groups will be reminded to follow the instructions about general good skin care of infants. Subjects will be asked if they agree to provide a saliva sample. If yes, a saliva sample will be collected from the inside of the infant's cheek at the 6 month visit and will be shipped to the laboratory of Dr. Irwin McLean at the University of Dundee, where it will be tested for gene defects in the skin barrier that might trigger the development of eczema. Defects in the gene called filaggrin have been shown to increase the risk of developing eczema. The samples will be identified by a code to protect your infant's identity. The saliva samples will be stored only for this study, and then the sample will be destroyed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Enrollment
100
Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
Subjects will apply Johnson\&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson\&Johnson cleanser.
Oregon Health & Science University Center for Health & Healing
Portland, Oregon, United States
Percentage of Participants With Cumulative Atopic Dermatitis Diagnosed by Investigator at 12 Months
Percentage of cumulative Atopic Dermatitis diagnosed by a blinded investigator at 12 months
Time frame: 12 months
Percentage of High Emollient Use
Patient-reported adherence to the emollient regimen in the intervention group and the treatment group. High emollient use was defined as applying the intervention or control emollient five or more days per week.
Time frame: 2, 6, 12, 18, and 24 months
Age at Onset of Eczema
Age of subject at onset of eczema
Time frame: Baseline through Month 24 Follow-up
Filaggrin Mutation Status
Filaggrin mutation status result
Time frame: 6 month visit
Transepidermal Water Loss (TEWL)
Transepidermal water loss (TEWL) to measure skin barrier function
Time frame: 2 month, 6 month, and 12 month visits
Skin Hydration (Skin Electrical Capacitance)
Determination of stratum corneum hydration from the dorsal forearm
Time frame: 2 month, 6 month, and 12 month visits
Skin pH
Skin pH, as measured using a pH probe
Time frame: 2 month, 6 month, and 12 month visits
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.